Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

IFOM ETS - The AIRC Institute of Molecular Oncology · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
immunotherapy
triple negative breast cancer metastatic, immunotherapy, atr inhibition, ceralasertib, durvalumab, nab-paclitaxel, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 912804
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.